Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CRISPR Therapeutics AG (CRSP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results -PDUFA target action date of December 8, 2023, for SCD and March 30, 2024, for TDT-"
06/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "of der CRISPR Therapeutics AG CRISPR Therapeutics AG with registered office in mit Sitz in Zug Zug I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sitz, Dauer und Zweck der Gesellschaft Art. 1 Corporate Name, Principal Office and Duration Art. 1 Firma, Sitz und Dauer Under the name CRISPR Therapeutics AG Unter der Firma CRISPR Therapeutics AG there exists a Company which is subject to the provisions of art. 620 et seq. of the Swiss Code of Obligations with registered office in Zug. The duration of the Company is unlimited. besteht für unbeschränkte Dauer eine Aktiengesellschaft gemäss Art. 620 ff. OR mit Sitz in Zug. Art. 2 Purpose Art. 2 Zweck The purpose of the Company is the research and development in the field of pharmaceutical pro..."
06/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Accepts Biologics License Applications for exagamglogene autotemcel for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - First CRISPR gene-editing filings to be accepted for review by FDA",
"Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association Congress - Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - - Data continue to demonstrate transformative and durable benefit - - Safety profile consistent with busulfan conditioning and autologous hematopoietic stem cell transplant –"
05/30/2023 144 Form 144 - Report of proposed sale of securities:
05/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results"
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/25/2023 144 Form 144 - Report of proposed sale of securities:
04/03/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023-"
03/29/2023 8-K Quarterly results
03/27/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "[***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601 of Regulation S-K. NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND CRISPR THERAPEUTICS AG Non-excLusive LICENSE AGREEMENT This NON-EXCLUSIVE LICENSE AGREEMENT is entered into as of March 23, 2023 by and between Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG . Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” RECITALS WHEREAS, CRISPR possesses certain Patents, Know-How, technology and exper...",
"Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes -Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- -CRISPR Therapeutics to receive $100M upfront payment plus milestone and royalty payments on potential future gene-edited hypoimmune T1D products -"
03/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Proprietary Information and Inventions Agreement 16",
"Investor Contact:"
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/10/2023 SC 13G/A ARK Investment Management LLC reports a 10% stake in CRISPR Therapeutics AG
02/10/2023 SC 13G/A Nikko Asset Management Americas, Inc. reports a 5.1% stake in CRISPR Therapeutics AG
02/03/2023 SC 13G/A Sumitomo Mitsui Trust Holdings, Inc. reports a 5.1% stake in CRISPR Therapeutics AG
11/01/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/01/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
09/27/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 - Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 – - EMA and MHRA submissions are on track for Q4 2022 – - Exa-cel granted Fast Track, Regenerative Medicine Advanced Therapy and Orphan Drug designations in the U.S., and Priority Medicines and Orphan Drug designations in Europe -"
08/08/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
07/13/2022 UPLOAD Form UPLOAD - SEC-generated letter:
06/23/2022 CORRESP Form CORRESP - Correspondence:
06/21/2022 8-K Quarterly results
06/13/2022 UPLOAD Form UPLOAD - SEC-generated letter:
06/13/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy